Grail

Grail Tangible Book Value per Share

The Tangible Book Value per Share of Grail (GRAL) as of Oct 16, 2026 is 66.13 USD. In the previous year, Tangible Book Value per Share was 12.48 USD — a change of 429.86% (higher).

Tangible Book Value per Share

66.13USD

YoY

429.86%

Last updated:

Tangible Book Value per Share of Grail is 2025 66.13 USD. Tangible Book Value per Share of Grail was 2024 12.48 USD. It decreases by 429.86% higher compared to the previous year.

The Grail Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
15.40 USD
Jan 1, 2019
14.12 USD
Jan 1, 2020
14.41 USD
Jan 1, 2021
82.93 USD
Jan 1, 2022
80.78 USD
Jan 1, 2023
1.80 USD
Jan 1, 2024
12.48 USD
Jan 1, 2025
66.13 USD
The Grail Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
66.13USD+429.86%
12.48USD+594.74%
1.80USD-97.78%
80.78USD-2.60%
82.93USD+475.38%
14.41USD+2.05%
14.12USD-8.30%
15.40USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grail Stock analysis

What does Grail do? Grail Inc, with ticker GRAL and ISIN US3847471014, is a US-based biotechnology company headquartered in Menlo Park. The company operates within the Health Care sector and has 910 employees. Grail Inc. went public on June 12, 2024. The company's website is https://www.galleri.com/. Grail Inc. focuses on early cancer detection through advanced technologies including next-generation sequencing, population-scale clinical studies, and machine learning. Its platform utilizes methylation-based approaches to support cancer screening and precision oncology, targeting multiple cancer types for early detection. The company's products include Galleri, a screening test for multi-cancer early detection, which helps guide healthcare decisions for cancer diagnosis. Grail Inc. aims to shift paradigms in cancer detection by identifying diseases at earlier stages, thereby alleviating the global burden of cancer. The company's approach integrates software, automation, and data analysis to enhance the continuum of care for cancer patients. Grail Inc. is engaged in developing solutions for cancer screening, risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring, and recurrence tracking. The company's work is centered on improving outcomes through early intervention and personalized treatment strategies. The focus on early detection aligns with efforts to reduce cancer mortality rates and improve patient survival rates globally. Grail Inc. operates with a technology-driven approach to revolutionize cancer care through innovative diagnostic tools and methodologies. Grail is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grail stock

Tangible Book Value per Share of Grail is 66.13 USD in 2025.

Tangible Book Value per Share of Grail changed from 12.48 USD to 66.13 USD, representing a 429.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Grail since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Grail

All Key Metrics — Grail